Mabel Rocio Miranda Echagüe

Mrs. Mabel Rocio Miranda Echagüe

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2026 in Cells
Verified
Journal Article
Open access
PDF file
IBIsabel María Vallejo Bermúdez
Isabel María Vallejo Bermúdez
Mabel Rocio Miranda EchagüeMabel Rocio Miranda Echagüe
Mabel Rocio Miranda Echagüe
SÁSilvia Fernández Álvarez
Silvia Fernández Álvarez
EAEster Irene Reina Alfonso
Ester Irene Reina Alfonso
LBLaura Blanca-Pariente
Laura Blanca-Pariente
Alejandra PeraAlejandra Pera
Alejandra Pera
CD57-expressing lymphocytes constitute a distinct subset of immune cells with enhanced cytotoxic and pro-inflammatory functions. Initially described in the context of chronic viral infections, most notably cytomegalovirus (CMV), these cells are now recognized as central contributors to immunosenescence and age-related immune dysregulation. Their progressive accumulation reflects prolonged antigenic exposure and sustained immune activation, thereby linking persistent viral infections with long-term disruptions of immune homeostasis. Emerging evidence indicates that CD57 expression denotes a state of terminal differentiation in both T and natural killer (NK) cell compartments, and is associated with cytotoxicity, altered cytokine secretion, and a pro-inflammatory phenotype. This review summarizes the phenotypic and functional characteristics of CD57+ lymphocytes, examines their association with CMV and other chronic viral infections, and explores their potential role in ageing and age-related diseases. Elucidating the biology of CD57+ lymphocytes in the context of chronic viral infections may provide novel insights into immune ageing and help identify potential targets for therapeutic strategies aimed at restoring immune balance in older adults.

9 January 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
Mabel Rocio Miranda EchagüeMabel Rocio Miranda Echagüe
Mabel Rocio Miranda Echagüe
GVGiacomo Vezzani
Giacomo Vezzani
EMElena Morandi
Elena Morandi
MPMelania Della Peruta
Melania Della Peruta
MSMirko Scordio
Mirko Scordio
OROmar Rossi
Omar Rossi
Rotaviruses are the primary cause of severe dehydrating diarrhea in infants and young children globally. Currently, several oral rotavirus vaccines are available; however, they have shown reduced effectiveness and quicker waning of protection in low- and middle-income countries (LMICs) compared to high-income countries (HICs). Both neutralizing and non-neutralizing antibodies against the middle (VP6) and outer layer capsid proteins (VP4 and VP7) are detected after infection, with higher titers being linked to disease protection. Historically, human derived rotavirus-specific monoclonal antibodies (mAbs) have been produced in an IgG1 scaffold, irrespective of whether their native scaffold was IgG or IgA. To explore the impact of antibody scaffolds on their functional activity we expressed mAbs targeting epitopes on VP8* or VP7 viral proteins in IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2 scaffolds (the latter either in a monomeric or in a dimeric IgA form). The mAbs were characterized for their binding affinity to the viral target and their functionality was evaluated in an in vitro neutralization assay using three different rotavirus strains (G1P[8], G2P[4], and G9P[8]), representing homologous and heterologous specificities. Our findings revealed that mAbs targeting the same epitope exhibited varying neutralization activities when expressed in different scaffolds and suggested an enhanced breadth of neutralization activity in the context of an IgA scaffold. These data suggest that scaffolds impact the ability of antibodies to neutralize rotavirus. These findings can assist vaccine design informing the use of different technologies or adjuvants to elicit more effective antibody classes and subclasses.

1 January 2026 in International Journal of Microbiology
Verified
Journal Article
Open access
PDF file
PMPamela Mongelós
Pamela Mongelós
MMMagaly Martínez
Magaly Martínez
NDNatalia Díaz
Natalia Díaz
VNValéria Talpe Nunes
Valéria Talpe Nunes
AVAdriana Valenzuela
Adriana Valenzuela
LMLaura Mendoza
Laura Mendoza
Human papillomavirus Type 16 (HPV16) variants are classified into four lineages (A–D) and 16 sublineages: A1–3 (European), A4 (Asian), B1–4 and C1–4 (African), and D1–4 (Asian‐American). This study investigated the genetic HPV16 variability through sequencing of the complete long control region (LCR), in 44 cervical samples from Paraguayan women, including 19 without cervical intraepithelial neoplasia grade 2 (<CIN2) and 25 with CIN2 or worse (CIN2+: 1 CIN2, 16 CIN3, and 8 invasive cancers). Sublineages A1 (81.8%), A4 (2.3%), D2 (2.3%), D3 (11.4%), and D4 (2.3%) were detected. A total of 48 point mutations were detected, of which 11 showed nominal association with CIN2+ ( p < 0.05), although none remained statistically significant after correction for multiple comparisons. Notably, most of these mutations were predominantly observed in non‐A1–A3 variants. An exploratory association was observed between non‐A1–A3 variants and the presence of CIN2+ ( p = 0.0065). Functional analysis revealed that the A4 variant, detected in a woman with cancer, exhibited the highest transcriptional activity (2.34 ± 0.78), followed by D3 (0.72 ± 0.21) and A1 (0.03 ± 0.02), corresponding to samples from women with CIN3 and without lesions, respectively. In conclusion, we report for the first time the detection of an A4 HPV16 variant in Paraguay, which exhibited the highest transcriptional activity among the variants analyzed. These findings suggest potential functional differences among HPV16 variants and are consistent with a possible relevance of non‐A1–A3 variants in cervical lesion severity. However, these results should be interpreted with caution as exploratory and hypothesis‐generating.

9 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
DGDenise Guerra
Denise Guerra
ECEdoardo Cherubini
Edoardo Cherubini
Mabel Rocio Miranda EchagüeMabel Rocio Miranda Echagüe
Mabel Rocio Miranda Echagüe
GMGiuseppe Maccari
Giuseppe Maccari
GAGabriele Anichini
Gabriele Anichini
EAEmanuele Andreano
Emanuele Andreano
Phenuiviruses which include Rift Valley Fever Virus (RVFV), classified by WHO as one of the top priority pathogens with outbreak potential, are emerging arthropod-borne viruses that pose an increasing threat to public health. In line with the “prototype pathogen” framework advanced by the NIAID, the sandfly-transmitted Toscana virus (TOSV) has been adopted as a prototype to advance understanding of relevant phenuiviruses and inform the development of broadly applicable medical countermeasures. In this study, we sought to isolate and characterize monoclonal antibodies (mAbs) elicited by natural TOSV infection to identify shared antigenic determinants. By employing the conserved envelope Gc glycoprotein as bait for antigen-specific B cell sorting, we recovered more than 1,450 memory B cells and identified 112 Gc-specific neutralizing mAbs. Over one-third of these mAbs exhibited cross-reactivity with RVFV, a genetically distinct phenuivirus. Selected mAbs provided prophylactic protection in a murine model of TOSV infection. Together, our findings establish Gc as an important target of protective neutralizing antibodies and provide insights that may guide the rational design of widely effective interventions, strengthening readiness against future phenuivirus outbreaks.